119 related articles for article (PubMed ID: 17128692)
1. Body mass index as a prognostic factor in endometrioid adenocarcinoma of the endometrium.
Gates EJ; Hirschfield L; Matthews RP; Yap OW
J Natl Med Assoc; 2006 Nov; 98(11):1814-22. PubMed ID: 17128692
[TBL] [Abstract][Full Text] [Related]
2. Expression of EGFR, HER-2/neu, P53, and PCNA in endometrioid, serous papillary, and clear cell endometrial adenocarcinomas.
Khalifa MA; Mannel RS; Haraway SD; Walker J; Min KW
Gynecol Oncol; 1994 Apr; 53(1):84-92. PubMed ID: 7909788
[TBL] [Abstract][Full Text] [Related]
3. Prognostic significance of progesterone receptor immunohistochemistry in endometrial carcinoma.
Fukuda K; Mori M; Uchiyama M; Iwai K; Iwasaka T; Sugimori H
Gynecol Oncol; 1998 Jun; 69(3):220-5. PubMed ID: 9648591
[TBL] [Abstract][Full Text] [Related]
4. The expression ratios of estrogen receptor α (ERα) to estrogen receptor β1 (ERβ1) and ERα to ERβ2 identify poor clinical outcome in endometrioid endometrial cancer.
Zannoni GF; Monterossi G; De Stefano I; Gargini A; Salerno MG; Farulla I; Travaglia D; Vellone VG; Scambia G; Gallo D
Hum Pathol; 2013 Jun; 44(6):1047-54. PubMed ID: 23266443
[TBL] [Abstract][Full Text] [Related]
5. Expression of estrogen receptor-alpha and -beta and progesterone receptor-A and -B in a large cohort of patients with endometrioid endometrial cancer.
Jongen V; Briët J; de Jong R; ten Hoor K; Boezen M; van der Zee A; Nijman H; Hollema H
Gynecol Oncol; 2009 Mar; 112(3):537-42. PubMed ID: 19108875
[TBL] [Abstract][Full Text] [Related]
6. Tumor-associated macrophages, epidermal growth factor receptor correlated with the triple negative phenotype in endometrial endometrioid adenocarcinoma.
Jiang XF; Tang QL; Shen XM; Li HG; Chen LH; Wang XY; Luo X; Lin ZQ; Jiang GY
Pathol Res Pract; 2012 Dec; 208(12):730-5. PubMed ID: 23122929
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of progesterone receptor immunohistochemistry for lymph node metastases in endometrial carcinoma.
Iwai K; Fukuda K; Hachisuga T; Mori M; Uchiyama M; Iwasaka T; Sugimori H
Gynecol Oncol; 1999 Mar; 72(3):351-9. PubMed ID: 10053107
[TBL] [Abstract][Full Text] [Related]
8. Prognostic significance of ER, PR, Ki67, c-erbB-2, and p53 in endometrial carcinoma.
Suthipintawong C; Wejaranayang C; Vipupinyo C
J Med Assoc Thai; 2008 Dec; 91(12):1779-84. PubMed ID: 19133508
[TBL] [Abstract][Full Text] [Related]
9. Is body mass index an independent risk factor of survival among patients with endometrial cancer?
Temkin SM; Pezzullo JC; Hellmann M; Lee YC; Abulafia O
Am J Clin Oncol; 2007 Feb; 30(1):8-14. PubMed ID: 17278888
[TBL] [Abstract][Full Text] [Related]
10. An intensive follow-up does not change survival of patients with clinical stage I endometrial cancer.
Gadducci A; Cosio S; Fanucchi A; Cristofani R; Genazzani AR
Anticancer Res; 2000; 20(3B):1977-84. PubMed ID: 10928137
[TBL] [Abstract][Full Text] [Related]
11. The outcome of stage I-II clinically and surgically staged papillary serous and clear cell endometrial cancers when compared with endometrioid carcinoma.
Cirisano FD; Robboy SJ; Dodge RK; Bentley RC; Krigman HR; Synan IS; Soper JT; Clarke-Pearson DL
Gynecol Oncol; 2000 Apr; 77(1):55-65. PubMed ID: 10739691
[TBL] [Abstract][Full Text] [Related]
12. Tumor budding and E-Cadherin expression in endometrial carcinoma: are they prognostic factors in endometrial cancer?
Koyuncuoglu M; Okyay E; Saatli B; Olgan S; Akin M; Saygili U
Gynecol Oncol; 2012 Apr; 125(1):208-13. PubMed ID: 22198340
[TBL] [Abstract][Full Text] [Related]
13. [Immunohistochemical profile of endometrioid adenocarcinoma of the uterus: ER, PR, HER-2, Ki-67 and their prognostic value].
Pozharisskiĭ KM; Samsonova EA; Ten VP; Maksimova NA; Urmancheeva AF
Arkh Patol; 2005; 67(2):13-7. PubMed ID: 15938112
[TBL] [Abstract][Full Text] [Related]
14. Tumor-associated macrophages correlate with progesterone receptor loss in endometrial endometrioid adenocarcinoma.
Jiang XF; Tang QL; Li HG; Shen XM; Luo X; Wang XY; Lin ZQ
J Obstet Gynaecol Res; 2013 Apr; 39(4):855-63. PubMed ID: 23106983
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathologic analysis of the prognostic factors in women with coexistence of endometrioid adenocarcinoma in the endometrium and ovary.
Nishimura N; Hachisuga T; Yokoyama M; Iwasaka T; Kawarabayashi T
J Obstet Gynaecol Res; 2005 Apr; 31(2):120-6. PubMed ID: 15771637
[TBL] [Abstract][Full Text] [Related]
16. Should grade 3 endometrioid endometrial carcinoma be considered a type 2 cancer-a clinical and pathological evaluation.
Voss MA; Ganesan R; Ludeman L; McCarthy K; Gornall R; Schaller G; Wei W; Sundar S
Gynecol Oncol; 2012 Jan; 124(1):15-20. PubMed ID: 21864888
[TBL] [Abstract][Full Text] [Related]
17. Is older age a poor prognostic factor in stage I and II endometrioid endometrial adenocarcinoma?
Fleming ND; Lentz SE; Cass I; Li AJ; Karlan BY; Walsh CS
Gynecol Oncol; 2011 Feb; 120(2):189-92. PubMed ID: 21112078
[TBL] [Abstract][Full Text] [Related]
18. Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma.
Silverman MB; Roche PC; Kho RM; Keeney GL; Li H; Podratz KC
Gynecol Oncol; 2000 Apr; 77(1):1-7. PubMed ID: 10739683
[TBL] [Abstract][Full Text] [Related]
19. Fatty acid synthase is a potential therapeutic target in estrogen receptor-/progesterone receptor-positive endometrioid endometrial cancer.
Rahman MT; Nakayama K; Ishikawa M; Rahman M; Katagiri H; Katagiri A; Ishibashi T; Iida K; Miyazaki K
Oncology; 2013; 84(3):166-73. PubMed ID: 23306391
[TBL] [Abstract][Full Text] [Related]
20. Clinico-pathologic comparison of type II endometrial cancers based on tamoxifen exposure.
Tergas AI; Buell-Gutbrod R; Gwin K; Kocherginsky M; Temkin SM; Fefferman A; Lengyel E; Yamada SD
Gynecol Oncol; 2012 Nov; 127(2):316-20. PubMed ID: 22835717
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
